| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9328133 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8338642 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US9757416 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US7767851 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5753706 | KERYX BIOPHARMS | Methods for treating renal failure |
Feb, 2022
(2 years ago) | |
| US8846976 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8754258 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8754257 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US9050316 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8299298 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Feb, 2024
(2 months ago) | |
| US8901349 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8609896 | KERYX BIOPHARMS | Ferric organic compounds, uses thereof and methods of making same |
Feb, 2024
(2 months ago) | |
| US8093423 | KERYX BIOPHARMS | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
Apr, 2026
(2 years from now) | |
| US10300039 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(6 years from now) | |
| US9387191 | KERYX BIOPHARMS | Ferric citrate dosage forms |
Jul, 2030
(6 years from now) | |
Auryxia is owned by Keryx Biopharms.
Auryxia contains Ferric Citrate.
Auryxia has a total of 15 drug patents out of which 12 drug patents have expired.
Expired drug patents of Auryxia are:
- US5753706
- US8846976
- US8754258
- US8754257
- US9050316
- US8299298
- US8901349
- US8609896
- US9328133
- US8338642
- US9757416
- US7767851
Auryxia was authorised for market use on 05 September, 2014.
Auryxia is available in tablet;oral dosage forms.
Auryxia can be used as control of serum phosphorus levels, control of serum phosphorous levels.
The generics of Auryxia are possible to be released after 21 July, 2030.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-790) | Nov 06, 2020 |
Drugs and Companies using FERRIC CITRATE ingredient
Market Authorisation Date: 05 September, 2014
Treatment: Control of serum phosphorous levels; Control of serum phosphorus levels
Dosage: TABLET;ORAL
AURYXIA family patents
